China’s BGI Teams Up With CHOP For Genomics Work In Rare Diseases
This article was originally published in PharmAsia News
China’s genomics leader, BGI, has furthered its U.S. presence with a collaboration with the Children’s Hospital of Philadelphia focusing on rare disease diagnostics.
You may also be interested in...
After announcing the intent to form a partnership a year ago, Merck & Co. announced Sept. 13, a collaboration with BGI (formerly the Beijing Genomics Institute) for discovery and development of biomarkers and genomic technologies
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.